Design, synthesis, and biological evaluation of novel AAK1/HDACs dual inhibitors against SARS-CoV-2 entry
Bioorganic Chemistry · 2024
DOI: 10.1016/j.bioorg.2024.107973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Nian-Dong Mao und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; School of Pharmacy, Hangzhou Normal Universi…. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Design, Antiviral Agents, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
AP2-associated protein kinase 1 (AAK1) is a crucial regulator of clathrin-mediated endocytosis, involved in various cellular processes, including viral infection. Histone deacetylases (HDACs) are essential in regulating gene transcription through the process of histone deacetylation and have become promising therapeutic targets for the treatment of cancer and viral infections. In this study, several AAK1/HDACs dual inhibitors based on our previous reported compounds were designed and synthesized, and the antiviral activity of these dual inhibitors were evaluated. Among them, compound 12 showed remarkable dual inhibitory activity against both AAK1 and HDACs, with IC50 values of 15.9 nM for AAK1, 148.7 nM for HDAC1, and 5.2 nM for HDAC6. Notably, this compound exhibited superior efficacy in suppressing SARS-CoV-2 entry into host cells compared to its close analogs 4, 13a, and 13b. Mechanistically, compound 12 attenuated AAK1-induced phosphorylation of adaptor protein-2 μ subunit (AP2M1) threonine 156, disrupting the direct interaction between AP2M1 and ACE2, thus inhibiting the CME-mediated SARS-CoV-2 endocytosis. Additionally, compound 12 increased the acetylation levels of H3K27 and α-tubulin, suggesting its potential as an epigenetic modulator. Overall, our findings propose compound 12 as a promising dual inhibitor against AAK1 and HDACs, highlighting its therapeutic potential in antiviral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Key Laboratory of Elemene Class…
- School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chine…
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China.
- School of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
- School of Basic Medical Science, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
- Fujian Provincial Drug Evaluation and Monitoring Center Xiamen Branch, Xiamen, Fujian 361013, China. Electronic address: wenwen2020211@outlook.com.
Zitieren
APA
Mao, N. D., Xu, Y., Yao, X., Gao, Y., Hui, Z., Che, H., Wang, C., Lu, J., Yu, J., Hu, S., Zhang, H., & Ye, X. Y. (2024). Design, synthesis, and biological evaluation of novel AAK1/HDACs dual inhibitors against SARS-CoV-2 entry. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107973
Vancouver
Mao ND, Xu Y, Yao X, Gao Y, Hui Z, Che H, et al. Design, synthesis, and biological evaluation of novel AAK1/HDACs dual inhibitors against SARS-CoV-2 entry. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107973
BibTeX
@article{Mao2024,
author = {Mao, Nian-Dong and Xu, Yueying and Yao, Xia and Gao, Yuan and Hui, Zi and Che, Hao and Wang, Chenchen and Lu, Jinshan and Yu, Jie and Hu, Suwen and Zhang, Hang and Ye, Xiang-Yang},
title = {Design, synthesis, and biological evaluation of novel AAK1/HDACs dual inhibitors against SARS-CoV-2 entry},
journal = {Bioorganic Chemistry},
year = {2024},
doi = {10.1016/j.bioorg.2024.107973}
}
EUVIMED